155 related articles for article (PubMed ID: 37864742)
1. "There should be one spot that you can go:" BRCA mutation carriers' perspectives on cancer risk management and a hereditary cancer registry.
Hynes J; Dawson L; Seal M; Green J; Woods M; Etchegary H
J Community Genet; 2024 Feb; 15(1):49-58. PubMed ID: 37864742
[TBL] [Abstract][Full Text] [Related]
2. Cancer prevention in cancer predisposition syndromes: A protocol for testing the feasibility of building a hereditary cancer research registry and nurse navigator follow up model.
Etchegary H; Pike A; Puddester R; Watkins K; Warren M; Francis V; Woods M; Green J; Savas S; Seal M; Gao Z; Avery S; Curtis F; McGrath J; MacDonald D; Burry TN; Dawson L
PLoS One; 2022; 17(12):e0279317. PubMed ID: 36548287
[TBL] [Abstract][Full Text] [Related]
3. Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.
Franceschini G; Di Leone A; Terribile D; Sanchez MA; Masetti R
Ann Ital Chir; 2019; 90():1-2. PubMed ID: 30872561
[TBL] [Abstract][Full Text] [Related]
4. Specialty Care and Counselling about Hereditary Cancer Risk Improves Adherence to Cancer Screening and Prevention in Newfoundland and Labrador Patients with
Roebothan A; Smith KN; Seal M; Etchegary H; Dawson L
Curr Oncol; 2023 Oct; 30(10):9367-9381. PubMed ID: 37887578
[TBL] [Abstract][Full Text] [Related]
5. A Microsimulation Model for Evaluating the Effectiveness of Cancer Risk Management for BRCA Pathogenic Variant Carriers: miBRovaCAre.
Petelin L; Hossack L; Mitchell G; Liew D; Trainer AH; James PA
Value Health; 2019 Aug; 22(8):854-862. PubMed ID: 31426925
[TBL] [Abstract][Full Text] [Related]
6. Uptake and timing of risk-reducing salpingo-oophorectomy among patients with BRCA1 and BRCA2 mutations.
Smith MJ; Gerber D; Olsen A; Khouri OR; Wang Y; Liu M; Smith J; Pothuri B
Am J Obstet Gynecol; 2021 Nov; 225(5):508.e1-508.e10. PubMed ID: 34171390
[TBL] [Abstract][Full Text] [Related]
7. Genetic, clinic and histopathologic characterization of BRCA-associated hereditary breast and ovarian cancer in southwestern Finland.
Pallonen TA; Lempiäinen SMM; Joutsiniemi TK; Aaltonen RI; Pohjola PE; Kankuri-Tammilehto MK
Sci Rep; 2022 Apr; 12(1):6704. PubMed ID: 35469032
[TBL] [Abstract][Full Text] [Related]
8. Dealing with the unexpected: consumer responses to direct-access BRCA mutation testing.
Francke U; Dijamco C; Kiefer AK; Eriksson N; Moiseff B; Tung JY; Mountain JL
PeerJ; 2013; 1():e8. PubMed ID: 23638402
[TBL] [Abstract][Full Text] [Related]
9. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
10. Exploring the role of a multidisciplinary hereditary gynecologic oncology clinic in epithelial ovarian cancer risk-reducing surgical decision-making practices: A mixed-methods study.
Casalino S; Bruce S; Serfas K; Altman AD; Kean S; Lambert P; McManus KJ; Hartley JN; Nachtigal MW
J Genet Couns; 2023 Jun; 32(3):728-743. PubMed ID: 36808790
[TBL] [Abstract][Full Text] [Related]
11. Ovarian cancer risk management in BRCA-mutation carriers: A comparison of six international and national guidelines.
Matan LS; Perri T; Kogan L; Brandt B; Meyer R; Levin G
Eur J Obstet Gynecol Reprod Biol; 2022 Nov; 278():166-171. PubMed ID: 36208522
[TBL] [Abstract][Full Text] [Related]
12. Genetic and clinical characterization of BRCA-associated hereditary breast and ovarian cancer in Navarra (Spain).
Ruiz de Sabando A; Urrutia Lafuente E; García-Amigot F; Alonso Sánchez A; Morales Garofalo L; Moreno S; Ardanaz E; Ramos-Arroyo MA
BMC Cancer; 2019 Nov; 19(1):1145. PubMed ID: 31771539
[TBL] [Abstract][Full Text] [Related]
13. How to manage BRCA mutation carriers?
Sabiani L; Barrou J; Mathis J; Eisinger F; Bannier M; Lambaudie E; Houvenaeghel G
Horm Mol Biol Clin Investig; 2020 May; 41(3):. PubMed ID: 32459193
[TBL] [Abstract][Full Text] [Related]
14. Interventions to improve psychosocial well-being in female BRCA-mutation carriers following risk-reducing surgery.
Jeffers L; Reid J; Fitzsimons D; Morrison PJ; Dempster M
Cochrane Database Syst Rev; 2019 Oct; 10(10):CD012894. PubMed ID: 31595976
[TBL] [Abstract][Full Text] [Related]
15. Attitudes and compliance of clinical management after genetic testing for hereditary breast and ovarian cancer among high-risk Southern Chinese females with breast cancer history.
Kwong A; Chu AT; Wu CT; Tse DM
Fam Cancer; 2014 Sep; 13(3):423-30. PubMed ID: 24623488
[TBL] [Abstract][Full Text] [Related]
16. Decision-making on preimplantation genetic diagnosis and prenatal diagnosis: a challenge for couples with hereditary breast and ovarian cancer.
Derks-Smeets IA; Gietel-Habets JJ; Tibben A; Tjan-Heijnen VC; Meijer-Hoogeveen M; Geraedts JP; van Golde R; Gomez-Garcia E; van den Bogaart E; van Hooijdonk M; de Die-Smulders CE; van Osch LA
Hum Reprod; 2014 May; 29(5):1103-12. PubMed ID: 24603131
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of risk-reducing surgeries in preventing hereditary breast and ovarian cancer.
Schrauder MG; Brunel-Geuder L; Häberle L; Wunderle M; Hoyer J; Reis A; Schulz-Wendtland R; Beckmann MW; Lux MP
Breast; 2017 Apr; 32():186-191. PubMed ID: 28214786
[TBL] [Abstract][Full Text] [Related]
18. [Comparison of hereditary breast and ovarian cancer syndrome and sporadic ovarian cancer in ovarian cancer BRCA mutations].
Duan RR; Sun LX; Zhao HW
Zhonghua Fu Chan Ke Za Zhi; 2021 Nov; 56(11):788-795. PubMed ID: 34823292
[No Abstract] [Full Text] [Related]
19. Perceptions of risk and reward in BRCA1 and BRCA2 mutation carriers choosing salpingectomy for ovarian cancer prevention.
Ghezelayagh TS; Stewart LE; Norquist BM; Bowen DJ; Yu V; Agnew KJ; Pennington KP; Swisher EM
Fam Cancer; 2020 Apr; 19(2):143-151. PubMed ID: 32096072
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
